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INTRODUCTION 
PREECLAMPSIA 
Preeclampsia is a multisystem disorder that is specific to human 
pregnancy. It is characterized  by the development of hypertension to the 
extent of 140/90 mm Hg or more on atleast two occasions 4 hours apart 
with proteinuria more than 300mg for 24hrs or urine proteinuria more 
than 1+ that occurs after 20 weeks of gestation in a previously 
normotensive and nonproteinuric woman [17]. It is associated with high 
maternal mortality and morbidity and increased risk of perinatal death, 
preterm birth, and intrauterine growth restriction. It has been reported to 
complicate 4–7% of pregnancies worldwide.  
There is extensive evidence that the reduction of uteroplacental 
blood flow in this syndrome results from the toxic combination of 
hypoxia, imbalance of angiogenic and antiangiogenic factors, 
inflammation, deranged immunity and oxidative stress. 
CYSTATIN C 
Cystatin C is a low molecular weight non glycosylated basic 
protein of 12.8kDa made of 120 amino acid residues expressed in all 
nucleated cells[20]. It is a potent inhibitor of lysosomal proteinases and 
probably one of the most important extracellular inhibitors of cysteine 
proteases. Cystatin C belongs to the type 2 cystatin gene family. 
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It is extremely sensitive to minor changes in GFR in the earliest 
changes of kidney disease. 
CREATININE 
Creatinine is a breakdown product of creatinine phosphate in 
muscle, and is usually produced at a constant rate by the body. Serum 
creatinine is an important indicator of renal health because it is an easily 
measured byproduct of muscle metabolism that is excreted unchanged by 
the kidneys[9]. 
Creatinine is removed from the blood chiefly by the kidneys 
primarily by glomerular filtration but also by proximal tubular secretion. 
Little or no tubular reabsorption of creatinine occurs. If the filtration in 
the kidney is deficient, creatinine blood levels rise. Therefore, creatinine 
levels in blood and urine may be used to calculate the creatinine 
clearance (CrCl), which correlates with the glomerular filtration 
rate (GFR). Blood creatinine levels may also be used alone to calculate 
the estimated GFR (eGFR)[11]. 
The GFR is clinically important because it is a measurement 
of renal function. However, in cases of severe renal dysfunction, the 
creatinine clearance rate will overestimate the GFR because 
hypersecretion of creatinine by the proximal tubules will account for a 
larger fraction of the total creatinine cleared. 
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REVIEW OF LITERATURE 
Pre-eclampsia is a multisystem disorder of unknown etiology 
characterized by development of hypertension to the extent of 140/90mm 
Hg or more with proteinuria after the 20th week in a previously 
normotensive non – proteinuric woman. It complicates 4%–7% of 
pregnancies worldwide and constitutes a major source of morbidity and 
mortality. Overall, 10%–15% of maternal deaths are directly associated 
with pre-eclampsia and eclampsia. The risk of pre-eclampsia is 2-fold to 
5-fold higher in pregnant women with a maternal history of this disorder. 
Depending on ethnicity, the incidence of pre-eclampsia ranges from 3% 
to 7% in healthy nulliparas and 1% to 3% in multiparas. Moreover, 
nulliparity and a new partner have been shown to be important risk 
factors. 
Diagnosis of Hypertension: 
Hypertension in pregnancy should be defined as: 
Systolic blood pressure greater than or equal to 140 mmHg  
Diastolic blood pressure of greater than or equal to 90 mmHg  
These measurements should be based on the average of at least two 
measurements, taken using the same arm, 4-6 hours apart. Elevations of 
both systolic and diastolic blood pressures have been associated with 
adverse fetal outcome and therefore both are important. Detecting a rise 
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in blood pressure from booking or preconception blood pressure, rather 
than relying on an absolute value, has in the past been considered useful 
in diagnosing preeclampsia in women who do not reach blood pressure of 
140 or 90 mmHg. Available evidence does not suggest that these women 
have an increased risk of adverse outcome. However, such a rise may be 
significant in women with other complications such as proteinuria and 
closer monitoring of such women is recommended. Severe hypertension 
should be defined as a systolic BP of >160 mmHg or a diastolic BP of 
>110 mmHg. 
MEASUREMENT OF PROTEINURIA: 
All pregnant women should be assessed for proteinuria. Urinary 
dipstick testing may be used for screening for proteinuria when the 
suspicion of preeclampsia is low. Approximate equivalence is:  
 1+ = 0.3 g/l  
 2+ = 1 g/l  
 3+ = 3 g/l 
4+ = 10g/l 
There is considerable observer error with visual dipstick 
assessment[17]. This can be overcome by the use of automated dipstick 
readers, which significantly improve both false positive and negative 
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rates. In the presence of hypertension, a reading of 1+ or more should 
prompt further evaluation. 
Diagnosis of Clinically Significant Proteinuria: 
The upper limit of a normal 24-hour urine protein excretion is 0.3g 
and is based on a 95% CI for urinary protein in pregnancy. However, 
there is considerable variation between laboratory assays for the 
quantification of proteinuria[9]. This combined with unknown errors and 
the delay associated with obtaining a 24-hour collection means that newer 
tests have potential advantages. An elevated protein creatinine ratio of 
greater than 30 mg/mmol correlates with a 24-hour urine excretion 
greater than 300mg and should be used to check for significant 
proteinuria. 
CLASSIFICATION OF HYPERTENSION IN PREGNANCY: 
American Congress of Obstetricians and Gynecologists (ACOG) 
classification of severity [2] 
 Mild-moderate: 
* Systolic BP of 140 to 159 mmHg systolic and/or 90 to 109 
mmHg diastolic and proteinuria is 300 mg/24 hours or ≥1+ 
(on 2 random urine samples, collected at least 4 hours apart); 
or protein:creatinine ratio is ≥0.3 mg/dL. 
 12 
* BP is 140 to 159 mmHg systolic and/or 90 to 109 mmHg 
diastolic and, in the absence of proteinuria, any of the 
following is present: 
* Thrombocytopenia, platelets count <100,000/Ul 
* Serum creatinine ≥1.1 mg/L or a doubling of the serum 
creatinine concentration in the absence of other renal disease 
* Impaired liver function, elevated blood concentrations of 
liver transaminases to twice normal concentration 
* Pulmonary oedema 
* Cerebral or visual disturbances. 
 Severe: 
* BP is ≥160 mmHg systolic and/or ≥110 mmHg diastolic (on 
2 occasions at least 6 hours apart, while the patient is lying 
on bed) and proteinuria is 300 mg/24 hours or ≥1+ (on 2 
random urine samples, collected at least 4 hours apart) or 
protein:creatinine ratio is ≥0.3 mg/dL. 
* BP is ≥160 mmHg systolic and/or ≥110 mmHg diastolic (on 
2 occasions at least 6 hours apart, while the patient is on bed 
rest) and in the absence of proteinuria, any of the following 
is present: 
* Thrombocytopenia, platelets count <100,000/uL 
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* Serum creatinine ≥1.1 mg/L or a doubling of the serum 
creatinine concentration in the absence of other renal disease 
* Impaired liver function, elevated blood concentrations of 
liver transaminases to twice normal concentration 
* Pulmonary oedema 
* Cerebral or visual disturbances. 
HELLP syndrome is a subtype of severe pre-eclampsia 
characterised by haemolysis (H), elevated liver enzymes (EL), and low 
platelets (LP).  
National Institute for Health and Care Excellence (NICE, UK): 
classification of severity[4]: 
Severity of hypertension in pregnancy is based on BP measurement 
alone. 
 Mild: BP is 140 to 149 mmHg systolic and/or 90 to 99 mmHg 
 diastolic. 
 Moderate: BP is 150 to 159 mmHg systolic and/or 100 to 109 
 mmHg diastolic. 
 Severe: BP is ≥160 mmHg systolic and/or ≥110 mmHg diastolic. 
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National High Blood Pressure Education Program (NHBPEP) 
Working Group, the classification is as follows[3] : 
 Gestational hypertension 
 Chronic hypertension 
 Preeclampsia/eclampsia 
 Superimposed preeclampsia (on chronic hypertension) 
Although each of these disorders can appear in isolation, they are 
thought of as progressive manifestations of a single process and are 
believed to share a common etiology. 
Gestational hypertension : 
The characteristics of gestational hypertension are as follows[3]: 
 BP of 140/90 mm Hg or greater for the first time during pregnancy 
 No proteinuria 
 BP returns to normal less than 12 weeks' postpartum 
 Final diagnosis made only postpartum 
  
 15 
Chronic hypertension : 
Chronic hypertension is characterized by either  
(1) BP 140/90 mm Hg or greater before pregnancy or diagnosed 
before 20 weeks' gestation; not attributable to gestational 
trophoblastic disease or  
(2) Hypertension first diagnosed after 20 weeks gestation and 
persistent after 12 weeks postpartum. 
Preexisting chronic hypertension may present with superimposed 
preeclampsia presenting as new-onset proteinuria after 20 weeks 
gestation[3]. 
Preeclampsia / eclampsia  
Preeclampsia/eclampsia is characterized by a BP of 140/90 mm Hg 
or greater after 20 weeks gestation in a women with previously normal 
BP and who have proteinuria (≥0.3 g protein in 24-h urine specimen). 
Eclampsia is defined as seizures that cannot be attributable to other 
causes, in a woman with preeclampsia[4]. 
Superimposed preeclampsia :  
Superimposed preeclampsia (on chronic hypertension) is 
characterized by  
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(1) New onset proteinuria (≥300 mg/24 h) in a woman with 
hypertension but no proteinuria before 20 weeks gestation 
and  
(2) A sudden increase in proteinuria or BP, or a platelet count of 
less than 100,000/mm3, in a woman with hypertension and 
proteinuria before 20 weeks gestation[4]. 
Risk Factors :  
Risk factors for preeclampsia are as follows : 
 Nulliparity 
 Age older than 40 years  
 Black race  
 Family history  
 Chronic renal disease  
 Chronic hypertension  
 Antiphospholipid antibody syndrome  
 Diabetes mellitus  
 Twin gestation (but unaffected by zygosity)  
 High body mass index  
 Homozygosity for angiotensinogen gene T235  
 Heterozygosity for angiotensinogen gene T235  
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Pathophysiology: 
During normal pregnancy, the following changes occur[19]: 
 The villous cytotrophoblast invades into the inner third of the 
 myometrium 
 Spiral arteries lose their endothelium and most of their muscle 
 fibers. 
These structural changes are associated with functional alterations, 
such that spiral arteries become low-resistance vessels, and thus less 
sensitive, or even insensitive, to vasoconstrictive substances. 
Pre-eclampsia has a complex pathophysiology, the primary cause 
being abnormal placentation. Defective invasion of the spiral arteries by 
cytotrophoblast cells is observed during pre-eclampsia.  
The following may be the abnormalities in preeclampsia[18]: 
1. Thecytotrophoblast invasion of the uterus is actually a unique 
differentiation pathway in which the fetal cells adopt certain 
attributes of the maternal endothelium they normally replace. In 
pre-eclampsia, this differentiation process goes awry.  
2. The abnormalities may be related to the nitric oxide pathway, 
which contributes substantially to the control of vascular tone. 
Inhibition of maternal synthesis of nitric oxide prevents embryo 
implantation. Increased uterine arterial resistance induces higher 
sensitivity to vasoconstriction and thus chronic placental ischemia 
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and oxidative stress. This chronic placental ischemia causes fetal 
complications, including intrauterine growth retardation and 
intrauterine death. In parallel, oxidative stress induces release into 
the maternal circulation of substances such as free radicals, 
oxidized lipids, cytokines, and serum soluble vascular endothelial 
growth factor 1[34]. These abnormalities are responsible for 
endothelial dysfunction with vascular hyperpermeability, 
thrombophilia, and hypertension, so as to compensate for the 
decreased flow in the uterine arteries due to peripheral 
vasoconstriction. 
Endothelial dysfunction is responsible for the clinical signs 
observed in the mother, like, 
 Impairment of the hepatic endothelium contributing to onset of the 
HELLP (Hemolysis, Elevated Liver enzymes and Low Platelet 
count) syndrome 
 Impairment of the cerebral endothelium inducing refractory 
neurological disorders 
 Eclampsia.  
3. Depletion of vascular endothelial growth factor in the podocytes 
makes the endotheliosis more able to block the slit diaphragms in 
the basement membrane, adding to decreased glomerular filtration 
and causing proteinuria[16].  
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4. Endothelial dysfunction promotes microangiopathic hemolytic 
anemia and vascular hyperpermeability associated with low serum 
albumin causes edema. 
5. Impairment of the maternal immune system prevents it from 
recognizing the fetoplacental unit. Excessive production of immune 
cells causes secretion of tumor necrosis factor alpha which induces 
apoptosis of the extravillous cytotrophoblast.  
6. The human leukocyte antigen (HLA) system also appears to play a 
role in the defective invasion of the spiral arteries. Women with 
pre-eclampsia show reduced levels of HLA-G and HLA-E[16].  
7. High levels of soluble fms-like tyrosine kinase 1 (sFlt-1), an 
antagonist of vascular endothelial growth factor and placental 
growth factor, have been found in women with pre-eclampsia. 
Accordingly, assays of sFlt-1, placental growth factor, endoglin, 
and vascular endothelial growth factor, all of which increase 4–8 
weeks before onset of the disease, may be useful predictors of pre-
eclampsia.  
The crucial issue to understand is that the prime mover of pre-
eclampsia is abnormal placentation. Two common theories appear to be 
interlinked, i.e., a genetic theory and an immunological theory. Several 
susceptibility genes may exist for pre-eclampsia. These genes probably 
interact in the hemostatic and cardiovascular systems, as well as in the 
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inflammatory response. Some have been identified, and in candidate gene 
studies they have provided evidence of linkage to several genes, like 
 Angiotensinogen on 1-q42–43  
 eNOS on 7q36 
Other main important loci are 2p12, 2p25, 9p13, and 10q22. 
Abnormalities in renal system in preeclampsia[7]: 
For some reasons known and unknown renal system bears an 
unique challenge in preeclampsia.  
In normal pregnancies changes observed in renal system are: 
 The glomerular filtration rate (GFR) is increased. This leads to a 
series of changes including the increase in urine output. Increase in 
blood volume in pregnancy and increase in renal circulation are 
both contributing to increased urine output.  
 There is more blood filtered in pregnancy therefore the renal 
system goes into an unstressed overdrive. 
During preeclampsia, the blood volume that is increased in 
pregnancy is constricted. Also, in preeclampsia the renal vascular system 
undergoes vasoconstriction as does the entire vascular system of the 
pregnant mother. The renal system which is all geared up to handle the 
increased load actually faces a reduced load due to vasoconstriction. As a 
result it gets precariously poised and has a tendency to get dried up. The 
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intensity and frequency with which this occurs depends on the severity of 
preeclampsia. It also depends on the intrinsic robustness of the renal 
system to bear the alterations. 
While many biochemical markers have been used to assess renal 
function in non pregnant subjects many of them become incompetent in 
pregnancy more so in preeclampsia.  
Serum uric acid assessment in preeclampsia has been done by 
different workers at different times to assess renal function. Over a period 
of time it has been recognized that uric acid is a strong reducing 
substance in the body. It has therefore a very limited role in reflecting the 
renal function in a preeclamptic subject. 
Pathological changes in kidneys occur in preeclampsia. The 
changes are due to vasospasm[13].  
While one is examining the pathological changes that are taking 
place in the kidneys – one cannot help but salute the pioneering work 
done by Sheehan and his team in the same. This group diligently studied 
and documented renal changes in subjects who died in pregnancy on 
postmortem. They compared 112 non- preeclamptic subjects who died of 
preeclampsia or eclampsia with those who died of other causes. They 
performed postmortems on these subjects within two hours of death. In 
this way, they successfully deduced the changes occurring as an 
aftermath of death. Thus their results were very accurate. Their accuracy 
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in the results could be understood from the fact that modern imaging 
techniques have also corroborated with the changes described by Sheehan 
and colleagues. Therefore even to date no discussion and pathology of 
preeclampsia is complete without taking into account the description of 
these workers. 
Gross changes in the kidneys: 
The kidneys appear pale and have a relatively enlarged cortex[13]. 
Microscopic changes in kidneys: 
1. The most characteristic glomerular feature is endotheliosis which is 
nothing but prominent glomerular endothelial swelling. Occlusion 
of glomerular capillary lumina occurs without any increase in 
cellularity and it gives a lobularly accentuated appearance to the 
glomerular tuft[22]. 
2. Swelling of naïve endothelial cells and to a lesser extent mesangial 
cells result in narrowed or occluded capillary lumen. Glomeruli are 
enlarged and solidified. 
3. Volume of glomeruli is slightly increased, yet since its cellularity 
remains relatively unchanged, an appearance of somewhat 
hypocellular glomeruli that has a “bloodless” appearance is 
classically described in preeclampsia due to the endotheliosis[22].  
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4. Mesangial hypercellularity or mesangial matrix wideningis not 
typically present but variable degrees of mesangiolysis is 
commonly noted. 
5. Due to hypoperfusion of the glomeruli from compromised 
arteriolar blood flow the glomerular tuft may have wrinkling of 
capillary loop with mild collapse/shrinkage. This change is often 
seen in the afferent arterioles. 
6. Prominence of visceral epithelial cells may be observed due to 
proteinuria; However, this finding depends on the severity of the 
proteinuria. The glomeruli can be either segmentally or globally 
involved, and kidney may be focally or diffusely affected, 
depending on severity of the disease.  
7. There is extensive glomerular capillary basement membrane 
replication in chronic hypertension. This feature is similar to the 
“tram track appearance” seen in membranoproliferative 
glomerulonephritis (MPGN) or in transplant nephropathy of renal 
allografts. These changes are the result of long term glomerular 
endothelial cell injury and are non specific. But unlike MPGN 
there is no immune complex mediated process in chronic 
hypertension 
8. The narrowed lumina may have fibrin platelet thrombi within them. 
This feature reduces blood flow in the afferent arterioles in the 
glomeruli causing glomerular ischemia .in the subacute phase, 
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resulting in scarring in the intima due to inflammation. This intimal 
concentric scarring give it an “onion skin appearance”[11]. 
Renal changes in preeclampsia on immunofluorescence microscopy: 
Thre are no specific features for preeclampsia. 
In the acute stages of the disease, thre may be deposition of fibrin 
and IgM, complement components along the capillary walls of glomeruli 
in the arterioles and the mesangium.The intensity of immunofluorescence 
somewhat correlates with the severity of activity of the disease. 
Renal changes in preeclampsia on electron microscopy: 
 Thickening of glomerular capillary walls due to endothelial cell 
swelling & subendothelial widening 
 Expanded lamina rara interna gives a pale flocculant appearance 
with collections of electron dense material. 
 Endothelial cells lose their fenestrations 
 Focal or widespred effacement of podocyte foot processes 
 Non specific glomerular capillary basement membrane wrinkling 
and thickening 
 Variable mesangial cell interposition 
 Appearance of basementmembrane redup lication due to presence 
of new glomerular basement membrane material. 
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Clinical presentation of preeclampsia: 
Diagnosis of preeclampsia may not be straightforward due to 
heterogeneity of symptoms and signs. 
Patients with mild preeclampsia may be asymptomatic 
Many patients are diagnosed only through routine screening 
Clinical and laboratory tests are done to identify severity of 
preeclampsia and its complications. 
Symptoms of imminent eclampsia[19]: 
1. Reduced urine output due to acute renal failure 
2. Headache due to cerebral edema 
3. Visual disturbances due to cerebral edema 
4. Tinnitus  
5. Vomiting 
6. Uterine contractions, bleeding per vaginum due to placental 
abruption 
7. Band like epigastric pain due to hepatic hematoma 
8. Difficulty in breathing and cough with expectoration due to 
pulmonary edema 
Clinical examination: 
1. Check consciousness and orientation 
2. Look for pallor 
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3. Measurement of blood pressure in resting state with the patient in 
sitting position or semi recumbent position, using an appropriate 
sized cuff 
4. Look for pedal edema and generalized edema 
5. Check height, weight and BMI 
6. Screen for weight gain 
7. Monitor pulse rate, temperature and respiratory rate 
8. Monitor urine output 
9. Obstetric examination: Fundal height should correspond to the 
period of gestation. Fundal height more than period of gestation 
suggests twins, hydramnios, molar pregnancy and these conditions 
are more commonly associated with hypertension in pregnancy. 
Fundal height less than the period of gestation is suggestive of fetal 
growth restriction and also may be associated with hypertension. 
10. Assess fetal well being by electrocardiotocography 
Laboratory tests : 
1. Complete blood count including platelet count 
2. Urine albumin by dipstick method or24 hour urinary protein 
3. Liver function test including enzymes aspartate transaminases 
(AST) and alanine transaminases (ALT) levels. 
4.  Kidney function tests including serum creatinine and uric acid 
levels. In severe cases it is advisable to do protein creatinine ratio 
and creatinine clearance. 
 27 
5. Lactate dehydrogenase (LDH) for the diagnosis of HELLP 
syndrome 
6. PT and PTTK-Only if platelet count is abnormal 
7. Fundus examination to rule out severity of the disease. 
8. Blood grouping and Rh typing 
All investigations are repeated once a week or fortnightly 
depending on the severity except urine albumin and blood pressure 
measurement which should be done daily[18]. 
Fetal monitoring: 
In addition to maternal investigations, fetal monitoring is also 
required.  
Fetal assessment includes  
1. Daily fetal movement count by the patient which should be more 
than 10 in 24 hours or more than 3 in one hour thrice a day 
2. Non-stress test(NST) 
3. Biophysical profile 
4. Umbilical artery and middle cerebral artery Doppler.  
These investigations are performed between 28-30 weeks of 
gestation initially and the biophysical profile/NST is repeated at least 
once a week till patient delivers.  
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The frequency may increase if hypertension becomes severe or 
Doppler shows changes suggestive of fetal growth restriction. 
Characteristics of severe and non-severe preeclampsia[36]: 
 
 
 
 
 
Management of non – severe preeclampsia: 
 
Initial evaluation: 
Elevated blood pressure readings should be confirmed 
Quantification of urine proteinuria should be done 
Laboratory tests: 
1. Full blood counts 
2. Renal function tests 
3. Liver function tests 
4. Serum electrolytes 
5. PT and PTTK-Only if platelet count is abnormal 
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Fetal assessment with ultrasound to monitor AFI, fetal growth, 
Doppler velocimetry 
This should be done once every month and thereafter at frequent 
intervals if any abnormalities are identified. 
Management: 
Pregnancy complicated by gestational hypertension is managed 
according to severity, gestational age and presence of preeclampsia. 
Indications for admission to a hospital and further evaluation: 
 The Development of proteinuria 
 Elevation of the blood pressure above 150/100 mm of Hg threshold 
 Decreased fetal movements 
 Abnormal symphisio fundal height 
 Development of maternal symptoms suggestive of end organ 
damage 
Patients with negative findings for abnormality in their weekly 
assessment may continue with the pregnancy until they reach 38 weeks of 
gestation. At this time labor induction is performed with the help of 
cervical ripening agents like dinoprostone/ oxytocin/artificial rupture of 
membrane or caesarean section offered to the patient depending on 
modified Bishop’s score. 
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Anti hypertensives should be given to maintain systolic blood 
pressure at 130-155mmhg and diastolic blood pressure at 80 – 105mmhg. 
The first line antihypertensive agent of choice is oral labetalol. It 
may be given orally in doses of 100 – 400mg every 8-12 hours.  
Alternatives are methyldopa, nifedipine, the choice of which have 
been left on the clinician as per their familiarity of use. 
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Management of mild preeclampsia (ACOG 2014) 
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Management of severe preeclampsia: 
The objectives for management are[10]: 
1. Termination of pregnancy with the least possible trauma to mother 
and fetus. As of now, the only cure for preeclampsia is termination 
of pregnancy. At best, it may be controlled only when it is of mild 
variety. It is dangerous tocontinue pregnancy in severe 
preeclampsia for more than 1-2 weeks. 
2. Birth of an infant who subsequently thrives 
3. Complete restoration of health to the mother 
Aims for the immediate management are: 
 To bring down the blood pressure to safe levels 
 Assess general condition for presence of immediate risk factors for 
 convulsions. 
 Assessment of the fetal wellbeing and reasonable maturity 
 With the help of investigations and monitoring of urine output 
assess the patient for presence or absence of multiorgan 
involvement and HELLP syndrome. 
Antihypertensive treatment for acute management of severe 
hypertension[3]: 
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Labetalol: 
 It is the medication of choice for treatment of acute severe 
hypertension in pregnancy and for maintenance treatment of 
hypertensive disorders during pregnancy. 
 It is an alpha and beta adrenergic blocker. 
 The ratio of alpha to beta blockade is approximately 1:3 for oral 
form and 1:7 for intravenous form. 
 It should be avoided in asthmatics and in patients with cardiac 
failure. 
 It is effective in the treatment of severe hypertension and can be 
given by continuous or intermittent intravenous infusion. 
 Oral dose -  100-400mg every 6-12 hours 
 For intermittent dosing, 20mg should be given intravenous bolus 
initially over a two minute period. Additional doses of 40 – 80mg 
may be given at 20minute intervals. The maximum effect of IV 
labetalol is reached 5 minute after injection. 
 For continuous IV use, 500mg of labetalol is added to 400ml 
normal saline solution and administered at an initial rate of 
20mg/hour. If the blood pressure does not fall to the expected range 
in 20 minutes, the dose is doubled and continued to be doubled 
every 20 minutes until the expected range is obtained or a 
maximum dose of 220mg/hour is given. The effective dose range is 
between 50 and 200mg/hour. 
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Hydralazine: 
 It acts directly on the arteriolar smooth muscle to reduce peripheral 
vascular resistance. 
 It is administered in intravenous boluses starting at 5mg and 
increasing by 5mg every 20 minutes upto 20mg. 
 The most frequent side effects are: decreased uteroplacental 
perfusion and hyperdynamic circulation. Recovery from these side 
effects can be seen after the drug is discontinued and the blood 
pressure rises. 
Nifedipine: 
 It is a calcium channel blocker. 
 It is an excellent peripheral vasodilator and a good tocolytic agent. 
 It lowers blood pressure by inhibiting the intracellular influx of 
calcium into cardiac and vascular smooth muscles and by 
decreasing peripheral vascular resistance. 
 It is rapidly absorbed after oral administration and reaches peak 
levels 30 minutes after ingestion. 
 The NHBEP and RCOG recommend a 10mg initial oral dose to be 
repeated after 30 minutes if necessary. If there are no side effects 
the medication may be given in 10-30mg doses every 4-6 hours 
according to the blood pressure response.Doses above 120mg/day 
are rarely necessary.  
 35 
Management of eclampsia[46]: 
Management includes following: 
1. Check vitals 
2. Place patient in lateral decubitus position to prevent aspiration. The 
bed rails should be elevated to prevent maternal injury. Padded 
tongue blade should be inserted between teeth to avoid injury to the 
tongue. 
3.  Quick history and examination. 
4.  Keep airway clean and patent by frequent oral suctioning. 
5.  Give oxygen by mask at 8-10 litres/minute, if convulsion occurs or 
pulse oximetry show shypoxia 
6.  Prevent convulsions further by maintaining silence, dim lights, and 
minimal noise 
7. Give loading dose of magnesium sulphate, 4 gm of 20% solution 
intravenously slowly over 5minutes and 5 gm of 50% solution 
intramuscularly in each buttock followed by a maintenance dose of 
5 gms IM in alternate buttocks every 4 hourly till 24 hours after 
delivery. 
8. Intravenous labetalol or oral nifedipine to bring down the blood 
pressure to moderate level. 
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9. Pulse oximetry: There is possibility of help from anesthetist if 
patient is not maintaining oxygen saturation on pulse oximeter or is 
having frequent convulsions. 
10. After the patient is stabilized, do per vaginum examination and 
decide on termination, preferably vaginal delivery by instilling 
dinoprostone gel if cervix is too unfavorable or oxytocin 
augmentation. 
11. It should be noted that cesarean section in eclampsia has higher 
morbidity and mortality than vaginal delivery. However, 
indications for cesarean delivery in eclampsia sometimes can be, 
though rarely (1) obstetric indication like transverse lie, 
malpresentation, placenta previa, cephalo pelvic disproportion (2) 
uncontrolled fits not responding to the anticonvulsants treatment 
and for termination of pregnancy if there is no immediate prospect 
of vaginal delivery despite induction of labor. 
The various regimens available for administration of magnesium 
sulphate in eclampsia are: 
1. PRITCHARD REGIMEN : 4 gm of 20% MgSo4 IV slowly over 5-
10 min followed by 5 gm50% MgSo4 IM into each buttock 
followed by5 gm 50% MgSo4 IM 4hrly to alternate buttock. 
2. SIBAI REGIMEN[46]: 6 gm MgSo4 intravenously over 20 min 
followed by 2 gm MgSO4 IV infusion.  
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3. ZUSPANREGIMEN: 4 gm MgSo4 intravenously over 5-10 min 
followed by 1gm/hr MgSO4 IV infusion.  
Monitoring for magnesium toxicity: 
 Urine output should be atleast 30ml/hour or 100ml in 4 hours 
 Deep tendon reflexes should be present 
 Respiration rate should be >14 breaths /minute 
 Pulse oximetry should be >96% 
Any change in these indices makes it necessary to reevaluate the 
rate of administration. 
Cystatin C: 
Cystatin C was first discovered in 1961 as an alkaline protein in 
normal cerebrospinal fluid. It is low molecular weight (13.3KDa) protein 
having renal excretion. The Cystatin C gene is so called “housekeeping 
gene“[12]. Unique among cystatins, it seems to be produced by all human 
nucleated cells. It is produced at a stable rate, which is unaffected by 
inflammatory processes, sex, age, diet, and nutritional status .The first 
correlation between GFR and Cystatin C was in the year 1985 .The 
synthesis is significantly increased by hyperthyroidism and by high doses 
of corticosteroids. 
Serum levels of cystatin C are less dependent on age, sex, race and 
muscle mass compared to serum creatinine levels. Cross-sectional studies 
have shown that serum levels of cystatin C are more precise in estimating 
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kidney functions than serum creatinine. This may be because creatinine is 
actively secreted by proximal renal tubules and hence glomerular 
filtration rate, calculated by creatinine clearance, is overestimated in 
severe renal dysfunction. Newman et al in the study concluded that 
cystatin C was more sensitive marker for small changes in GFR. In a 
systematic review, Roos et al reported that Cystatin C was a reliable 
marker of GFR in patients with mild to moderate renal function 
impairment and also had higher chance of detecting true renal 
impairment. 
Serum levels of Cystatin C are increased in normal pregnancy, 
especially in the third trimester. This has been attributed to renal handling 
of low molecular weight proteins in conjunction with decreased GFR and 
increased synthesis by feto-placental unit or generalized phenomenon. 
The levels of Cystatin C are further increased in pre-eclampsia, 
correlating with functional and structural changes in kidneys. A study by 
Strevens et al. demonstrated that maternal serum levels of Cystatin C was 
a good marker for most onsets and severity of pre-eclampsia. In a renal 
biopsy study Cystatin C levels were shown to correlate with degree of 
glomerular endotheliosis, a typical histologic feature of pre-eclampsia. 
Since degree of endotheliosis has been considered to determine the 
severity of pre-eclampsia, it has been hypothesized that serum levels of 
Cystatin C can offer information regarding severity of pre-eclampsia. In 
the normal kidney, cystatin C is freely filtered through glomerular 
 39 
membrane and then almost completely reabsorbed and degraded by 
proximal tubular cells. Therefore, the plasma concentration of cystatin C 
is almost exclusively determined by GFR, making cystatin C an excellent 
indicator of GFR. Studies of the serum level of cystatin C in large patient 
cohorts have failed to correlate serum level to any pathophysiological 
states besides those affecting  GFR. 
Characteristics of an ideal GFR marker [51]: 
 Demonstrates the early and potentially reversible decrease of GFR 
 Independent of diet and hormonal or inflammatory changes  
 No tubular secretion  
 Low influence by muscle mass, gender and race  
 Independent of age for children above 1 year and adults  
 Demonstrates the decrease of GFR in old persons  
 Mirrors the diurnal GFR variation  
 Elucidates filtration quality and life expectancy 
Cystatin C as a marker of GFR: 
The interest in cystatin C as a marker of renal function has 
increased tremendously over the last few years and the number of articles 
and reviews about cystatin C continues to grow. Numerous studies and a 
meta-analysis incorporating 4,492 subject samples, comparing the use of 
serum cystatin C and creatinine as markers of GFR have shown that 
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serum cystatin C is clearly superior to serum creatinine as a marker of 
GFR. 
Advantages of Cystatin C as a marker of GFR than creatinine[38]: 
1. Cystatin C responds more quickly to changes in the GFR than 
creatinine, which is not a sensitive marker for early decline in 
GFR.  
2. A substantial proportion of patients with reduced GFR display 
serum creatinine levels within the normal range and even a 50% 
reduction of GFR is not infrequently associated with a normal 
concentration of serum creatinine. Cystatin C is accurate in this 
"creatinine-blind area" helping the clinician to get an earlier 
indication of deteriorating renal function, and thus allowing the 
possibility of taking preventive action.  
3. Cystatin C does not have the previously mentioned limitations of 
creatinine, and its measurement is a much simpler way of assessing 
renal function than methods such as iohexol clearance. 
4. A particularly important advantage of cystatin C as a marker of 
GFR is that it can also be used to evaluate GFR in patient 
populations for whom it is difficult to obtain an accurate 
assessment of GFR based on the creatinine value.  
5. Estimation of GFR from cystatin C helps clinicians when a fast 
estimate of a patient's renal function is needed to calculate the 
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correct amount of antibiotics or cytotoxic drugs for the individual 
patient, for instance, before initiating treatment, and also for 
monitoring patient response during and after therapy. Cancer 
therapeutics, in particular, have the potential to inflict severe 
damage to the kidneys. An early indication of renal dysfunction 
would allow the oncologist to adjust the drug dosage before 
irreparable kidney damage had occurred. 
6. In contrast to serum creatinine, serum cystatin C is unaffected by 
muscle mass. This means that selected patient groups, whose 
muscle mass is either reduced or undergoes rapid change, may 
particularly benefit from the use of cystatin C for estimating the 
GFR. This is true for children and the elderly.  
7. The reference range for serum creatinine increases with age up to 
the end of puberty and has to be adjusted for gender from puberty 
onwards. In contrast, the reference range for serum cystatin C is 
identical for men, women and children as the cystatin C level is 
constant after the age of one and virtually identical to the reference 
range for adults.  
8. In the first years of life, renal function matures physiologically. 
Accordingly high cystatin C concentrations have been found at 
birth, followed by a rapid decline after birth reflecting maturation 
of kidney function. Unlike serum creatinine, cystatin C can thus be 
used to assess the GFR of newborns and even of the foetus. 
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9. GFR decreases with age as the nephrons start to decrease from 
about the age of 50. At approximately the same age, muscle mass 
also begins to decline. In the elderly, serum creatinine is 
notoriously unreliable as an indicator of GFR because the daily 
production of creatinine is diminished as a result of the reduced 
muscle mass. 
10. In certain clinical situations, the influence of muscle mass can be 
essential, for instance when diagnosing reduced GFR in paralysed 
patients. This has been investigated in patients with spinal cord 
injury who have varying degrees of muscle atrophy. The results 
show that cystatin C is much more reliable as a marker of renal 
function for group of patients compared to creatinine . 
11. Diabetes is a highly complex disorder with many ramifications and 
is the commonest cause of kidney failure in younger people 
globally. Treatment comprises dialysis or kidney transplantation. If 
early damage to the kidneys can be detected, preventive action can 
then be taken. Cystatin C has been reported to be advantageous 
compared with serum creatinine for the detection of mild diabetic 
nephropathy, whereas the two markers were equally efficient in 
detecting advanced diabetic nephropathy. 
12. Cystatin C has been measured before and after chemotherapy in 
cancer patients. The results show that serum cystatin C is a 
superior marker to serum creatinine for the estimation of GFR, 
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independent of the presence of metastases, and independent of 
chemotherapy. 
13. Cystatin C can be used to characterise glomerular function in 
children with cancer. In multiple myeloma, a study has 
demonstrated no correlation between cystatin C and tumour 
burden. 
14. Cystatin C could be used as a valuable parameter in the monitoring 
of pregnancies complicated by pre-eclampsia. There is a real need 
for sensitive and specific diagnostic tests for pre-eclampsia. During 
uncomplicated pregnancy, the renal-flow progressively increases, 
leading to about 40% higher GFR than in a non-pregnant woman. 
Because pre-eclampsia is characterised by a decrease in GFR, 
kidney function needs to be monitored closely to ensure timely 
delivery before the development of toxaemia and serious kidney 
tissue injury. Cystatin C has been shown to provide superior 
diagnostic accuracy for pre-eclampsia compared to serum urate and 
creatinine, and cannot only be used as a marker for impaired renal 
function, but also for the degree of glomerular endotheliosis (the 
only consistently found pathological lesion in pre-eclampsia). 
Thus, cystatin C seems to be useful for optimising the timing of 
delivery. 
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Cystatin C Immunoassay: 
Cystatin C Immunoassay is intended for the quantitative 
determination of cystatin C in human serum and plasma by turbidimetry 
and nephelometry. The assay is based on particle-enhanced immune 
turbidimetry. The measuring range is optimised to 0.4 - 7.5 mg/L, which 
covers the concentration range in normal and diseased states[42]. The 
assay can be performed in most clinical chemistry analysers available in 
the market and the total assay time is approximately 10 minutes. This 
enables cystatin C to be measured 24 hours/day in most clinical chemistry 
laboratories.  The reagents on board the instrument and the calibration 
curve stored in the instrument remain stable for up to 90 days. 
There is currently no international reference material available for 
cystatin C, but the International Federation of Clinical Chemistry (IFCC) 
has recently established a working group on standardisation of Cystatin 
C. 
PREDICTION OF  PREECLAMPSIA: 
Uterine artery Doppler:  
A well-known mechanism of pathophysiology of preeclampsia is 
impaired trophoblastic invasion of the spiral arteries which increases 
impedance of flow to uterine arteries[24]. Several studies have shown 
that evidence of reduced uterine flow, is associated with the development 
of preeclampsia.  
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Elevated level of second trimester β-human chorionic gonadotropin 
(β-HCG) have been identified in patients at risk for hypertensive 
disorders during pregnancy. Another study demonstrated that in presence 
of a diastolic notch, the association of serum screening with alfa-feto-
protein and human chorionic gonadotropin, improves sensitivity and 
positive predictive value to 91% and 41% respectively.  
Regarding the placental protein-13 (PP-13), initial studies showed 
significantly decrease in preeclamptic women, recently another study did 
not show any relationship betweenPP-13 levels and preeclampsia. 
Akolekar et al studied placental protein-13 (PP-13) associated with 
pregnancy associated pregnancy protein-A (PAPP-A) and uterineartery 
Doppler in first trimester in 200 preeclamptic patients and in 410normal 
pregnancies showing reduction in PP-13 levels during early preeclampsia 
but not in latepreeclampsia with  positive predictive value for early 
preeclampsia of 75%, while for late preeclampsia of 49%. Though in 
preeclampsia PAPP-A was reduced and uterine velocimetry Doppler was 
elevated, combination of these parameters with PP-13 does not look to 
improve sensitivity of PP-13[39]. 
Inspite of the promising results, heterogeneity between studies 
regarding gestational age at the time of study or selected population has 
lead us to incline towards the combination of ultra sonographic and 
biochemical markers as screening procedure for preeclampsia.  
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Maternal echocardiography:  
In pregnancy changes happen in haemodynamic and cardiovascular 
system within intial vasodilatative adaptation of the maternal 
cardiovascular system which begins in Ist trimester as a result of invasion 
by spiral arteries by the trophoblast. Indeed remodelling in the spiral 
arteries contributes to 20% to 26% to the total reduction of systemic 
vascular resistance in the second trimester. Another change is in body 
composition with increase in blood volume. An analysis on multi 
frequency bioelectrical impedance, documented that the body water, 
extracellular water increased significantly and increasing from first half 
to the later half of pregnancy. 
Cardiovacular and haemodynamic modifications include elevated 
pre-load, reduced after-load, an increased compliance of vascular tree and 
a ventricular remodelling at the level of heart. We have therefore increase 
in blood volume to occupy the enlarged vascular bed. On the other hand, 
inadequate placentation and failure of haemodynamic adaptation was 
identified to base of pathologic process that leads to complications of 
pregnancy. Already in a study concluded that in preeclamptic women, 
along with the cardiac output, a high peripheral resistance can be 
observed and in those subjects with a reduced cardiac output low birth 
weight could occur. Another study observed that patients with fetal 
growth restriction (FGR) had a smaller diameter of left atrium and failure 
of cardiac output in early pregnancy. 
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The study group of Valensise designed a different thesis to evaluate 
the predictive value of some echocardiographic parameters for 
abnormalities in uterine artery Doppler and its relation to maternal and 
fetal complications. 
Echoparameters of cardiac changes in pregnancy may be, in 
normotensive women, an important marker of pregnancy complications 
& of predispostion to cardiac diseases. 
Provocative pressor tests: 
These are tests which assess blood pressure increase in response to a 
stimulus. They are cumbersome and time consuming. Sensitivities of all 
these tests range from 55 to 70% with specificity of 85%. They include: 
1. Angiotensin sensitivity test: 
The abnormal vascular reactivity of patients destined to develop 
preeclampsia may be detected several weeks before the development of 
clinical signs and symptoms and the degree of sensitivity to angiotensin II 
may be used as a screening test to identify the patients at risk.  
2. Roll over test: 
It measures the hypertensive response in women at 28 to 32 weeks who 
are resting in the left lateral decubitus position and then roll over to a 
supine position. A positive test is an elevation of 20mmHg or more of 
blood pressure when patients roll over from the lateral to the supine 
position 
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3. Urinary calcium: 
Several studies have demonstrated that preeclampsia is associated 
with hypocalciuria. A urinary calcium concentration equal to or less than 
12mg/dl in a 24 hour collection has positive and negative predictive 
values of 85 and 91% respectively, for the diagnosis of preeclampsia. 
Determination of calcium creatinine ratio in a randomly obtained urine 
sample seems to be accurate as 24 hour collection. 
New biochemical markers: 
In obstetrical practice a long-term objective is to identify ideal 
maternal biomarkers for preeclampsia, but it is very difficult because the 
“ideal marker” requires the coexistence of different characteristics: non 
invasiveness, high sensitivity and specificity, high positive predictive 
value to predict disease prognosis. Currently we have a plethora of 
studies intended to identify an ideal biomarker, however differences in 
the studied populations, in the methodologies and in the results 
interpretations, make it difficult to perform a systematic analysis of all the 
markers.  
Research of these new emerging biomarkers arises from the new 
model of pathogenesis of preeclampsia which places the focus not longer 
on vasoconstrictive phenomenon but on the angiogenesis process. 
Among proangiogenic factors there are vascular endothelial growth 
factor (VEGF) and placental growth factor (PlGF), among antiangiogenic 
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factor there are soluble endoglin (sEng) and soluble fms-like tyrosine 
kinase 1 receptor (sFlt-1).  
Cells expressing VEGF are located near fenestrated endothelia and 
the inhibition of VEGF leads to pathological conditions in many organs 
with fenestrated endothelia (e.g., liver, kidney, choroid plexus etc.) as 
observed in severe preeclampsia. PlGF is expressed mainly by placental 
cells and its levels increase from the second to third trimester. Both 
VEGF and PlGF bind VEGF receptor family, named Flt-1 and KDR. 
PlGF binds more actively Flt-1, while VEGF binds KDR. It has been 
suggested that sFlt-1 acts modulating VEGF availability. 
This evidence confirms the antiagiogenic role of soluble form of 
VEGF-PlGF receptor sFlt-1.  
sFlt-1bindsthese angiogenic factors and inhibits their vasodilatory 
effect. Other anti-angiogenic factor is sEng. In animal studies it allows 
the formation of endothelial tube and increases capillary permeability and 
could be responsible of hypertension, nephrotic syndrome and liver 
dysfunction during preeclampsia. 
A recent review reported significant changes in levels of sFlt-1, 
PlGF and sEng in preeclamptic patients, but with a different time course, 
earliest in the first trimester for PlGF and later for sFlt-1 and sEng.  
More recently the level of placental growth factor (PIGF) is 
evaluated in pregnancy complicated by hypertension disease and it has 
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been found that a positive PIGF test can predict delivery before 37 weeks 
in over 90% of pregnant women with hypertensive disease. Therefore a 
low level of PIGF could be used before 35 weeks, in hypertensive 
women, to evaluate the risk of pregnancy complications. Also sEng level 
seems to be a prognostic, and its level appears correlated with severe 
preeclampsia or eclampsia. Despite this evidence, there aren’t yet 
conclusive data on their diagnostic capability, on the cut-off of normality 
and on the time or the strategy to measure these markers. 
Regarding diagnostic capability, a recent extensive study conducted 
on 2200 patients reported for PlGF and sFlt-1 at first trimester, a 
sensitivity of 55% and 57% respectively and a specificity of 43% and 
40% respectively and this result doesn’t improve later in pregnancy. It is 
evident that the predictive positive value is too low to use this marker at 
first trimester as screening of preeclampsia. Other strategies in measuring 
the angiogenic factors have been proposed: a longitudinal evaluation and 
ratio between two factors.  
Indeed in preeclamptic women it has been demonstrated an increase 
from first to second trimester of sFlt-1, sEng and PlGF, on the other hand 
several studies, based on the observation that levels of PlGF and sFlt-1 
are altered together in preeclampsia, proposed a ratio between sFlt-1 and 
PlGF (sFlt-1:PlGF) and between PlGF and sEng (PlGF:sEng) reporting 
an important improvement in sensitivity (88.5% and 100% respectively) 
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and in specificity (88.5% and 98% respectively). Despite these promising 
results, larger studies are needed to confirm these finding. 
Biomarkers in preeclampsia: 
Autoantibodies: 
Gant et al identified hypersensitivity to infused Angiotensin II in 
preeclamptic patients. However, circulating levels of Angiotensin II are 
not increased in preeclampsia. Instead, immunoglobulins from 
preeclamptic women increased the beating rate of neonatal rat 
cardiomyocytes. These immunoglobulins contained Angiotensin II type 1 
(AT1) autoantibodies that stimulate the Angiotensin-receptor. The 
increased heartbeat rate could be blocked by treatment with losartan and 
it could be demonstrated that the autoantibodies bind to the second 
extracellular loop of the AT1 receptor. AT1 agonistic autoantibodies are 
not only found in preeclampsia but also in antibody mediated kidney 
transplant rejection. In kidney-transplant recipients who had severe 
allograft dysfunction without anti-HLA antibodies but detection of AT1 
agonistic autoantibodies rejection was accompanied by accelerated 
hypertension and convulsions. It is proposed that similar mechanisms 
might be involved in preeclampsia and refractory allograft rejection and it 
was found that one rejecting kidney-transplant recipient had had 
preeclampsia 16 years earlier. 
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Adrenomedullin: 
Pregnancy is associated with high concentrations of 
adrenomedullin in maternal and foetal blood and in the amniotic fluid. 
Adrenomedullin has a potent and long-lasting hypotensive effect when 
injected intravenously in anaesthetised rats. Hata et al measured 
circulating adrenomedullin concentrations in preeclampsia and 
normotensive pregnant women and showed that adrenomedullin 
concentrations are significantly lower in preeclamptic women. 
Podocyturia: 
Renal involvement in preeclampsia can be at least partly explained 
by impaired podocyte function. Podocytes are the major source of VEGF 
in the glomerulus. Podocyte-derived VEGF has paracrine functions on 
endothelial cells as well as autocrine functions on the podocytes 
themselves. New data suggest that detection of podocyturia might serve 
as an early diagnostic marker for preeclampsia prior to the development 
of proteinuria and hypertension. Garovic et al showed that podocyturia is 
present at delivery in women with preeclampsia[53]. Podocyturia also 
had a significantly greater sensitivity and specificity for the subsequent 
diagnosis of preeclampsia than any single angiogenic marker or a 
combination thereof in the second trimester. A strong correlation was 
found by Aita et al between the number of podocytes lost in urine and 
blood pressure, but no correlation with proteinuria. Several markers have 
been used in different studies to detect podocyturia. Nevertheless, it is 
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important to keep in mind that the expression of marker proteins does not 
allow a definite allocation of the involved glomerular cell types. De- or 
transdifferentiation and detachment of cells as well as changes in the 
urine milieu have a direct effect on marker protein expression. According 
to Skoberne et al, the urine markers most reliable for assessing disease 
activity of certain glomerular diseases are PDX- or CD68-positive cells. 
mRNA: 
Recently, quantitative polymerase chain reaction for podocyte-
specific markers was found to be a rapid method to detect preeclampsia. 
Significantly elevated mRNA levels of nephrin, podocin, and VEGF were 
detected in preeclamptic women compared with healthy controls. 
Placental protein 13: 
Placental protein 13 (PP13) is a member of the galectin super 
family and is important for differentiation and proliferation. Than et 
al[47] found reduced PP13 mRNA levels in placentas obtained from 
patients with preeclampsia and HELLP syndrome in the first trimester 
compared to controls. Blood levels of PP13 mRNA were also 
significantly lower in preeclampsia compared to controls. 
Pregnancy associated plasma protein-A: 
Pregnancy associated plasma protein-A (PAPP-A) is mainly 
produced by the placental trophoblasts. PAPP-A and PP13 serum levels 
were significantly lower in the first and second trimesters in women who 
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developed preeclampsia. First-trimester PAPP-A provided a prediction 
for preeclamspia when combined with uterine artery pulsatility measured 
by Doppler velocimetry. 
Activin A and inhibin A: 
During the first trimester of pregnancy, the foeto-placental unit is 
the main source of circulating activin A and inhibin A. Activin A 
enhances Follicle-stimulating hormone (FSH) biosynthesis and secretion 
and is involved in the control of trophoblast cell differentiation in the first 
trimester. Inhibin A down regulates FSH synthesis and inhibits FSH 
secretion. Activin A seems to be a sensitive marker for the risk of later 
development of preeclampsia at 21-25 weeks of gestation. Inhibin A is 
thought to be more sensitive than activin A in predicting cases of early-
onset preeclampsia at 15-19 weeks of gestation. 
P-selectin: 
P-selectin belongs to the group of cell adhesion molecules. It is 
expressed in granules of platelets and the Weibel-Palade bodies of 
endothelial cells and is involved in leukocyte-endothelial interactions. 
The P-selectin concentration was found to have a negative predictive 
value of almost 99% for preeclampsia. Mean plasma P-selectin 
concentrations were significantly elevated at 10-14 weeks of gestation in 
women who later developed preeclampsia. Wang et al suggested that the 
increase in neutrophil-endothelial adhesion and activation seen in 
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preeclampsia is at least in part due to up-regulation of P-selectin. This 
would be in line with the theory that preeclampsia reflects an excessive 
maternal inflammatory response to pregnancy. 
Pentraxin 3: 
Another inflammatory molecule involved in preeclampsia is 
Pentraxin 3. It is expressed in response to inflammatory stimuli by 
endothelial cells, monocytes, macrophages and fibroblasts. Elevated 
maternal plasma levels of pentraxin 3 in preeclamptic in comparison to 
normal pregnancies could represent altered endothelial function. The 
increase in maternal plasma develops from 11th to 13th week of gestation 
in women with subsequent preeclampsia. 
Fibronectin: 
Maternal plasma fibronectin levels of patients with preeclampsia 
were significantly higher than those of healthy pregnant women. 
Significant elevations in fibronectin levels with an extra type III domain 
occurred in the first trimester before clinical evidence of preeclampsia. 
Fibronectin plays a major role in embryonic development, cell adhesion, 
growth, migration and differentiation. 
Heat-shock proteins: 
Heat-shock proteins (Hsps) are highly conserved molecules that 
have chaperone functions. Circulating Hsps may also be cytoprotective, 
as exogenous Hsp70 increases the survival and protects from apoptosis in 
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stressed arterial smooth muscle cells. Fukushima et al reported 
significantly higher Hsp70 serum levels in preeclampsia. Higher serum 
levels of Hsp70 were also found in patients with early onset of severe 
preeclampsia. The difference in serum Hsp70 concentration between 
preeclamptic patients and the control group was statistically significant in 
each gestational age. Thus, Hsp70 might not only be a marker but also 
play a role in the pathogenesis of preeclampsia. 
Fms-like tyrosine kinase 1/ placental growth factor: 
Gene expression profile studies identified the regulation of soluble 
fms-like tyrosine kinase 1 (sFlt-1) in preeclampsia. SFlt-1 binds and 
antagonises vascular endothelial growth factor (VEGF) and placental 
growth factor (PlGF). 
The described functions of VEGF include induction of matrix 
metalloproteinases, regulation of angiogenesis, lymphangiogenesis and 
hematopoiesis and cell signalling. Serum concentration of sFlt-1 
decreases from 8-12 weeks to 16-20 weeks of gestation, gradually 
increases at 26-30 weeks of gestation and rapidly elevates at 35-39 weeks 
of gestation in normal pregnancy. 
SFlt1 concentrations increased gradually throughout pregnancy in 
women with preeclampsia and was significantly higher between 25 and 
28 weeks of gestation in women with preeclampsia than in women with 
normal pregnancies or isolated hypertension. Of note, sFlt1 are high 5-6 
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weeks prior to the onset of preeclampsia and correlate with the severity of 
disease. In rats sFlt-1 infusion increased vascular and placental oxidative 
stress, decreased maternal circulating VEGF and nitric oxide and reduced 
fetal weight. 
Serum concentration of PlGF increases gradually from 8 weeks 
until 29-32 weeks of gestation and then decreases at 33-40 week of 
gestation in normal pregnancy. PlGF levels in women who later 
developed preeclampsia were significant lower than those of controls 
from 13-16 weeks of gestation until delivery. As the change of PlGF 
occurs earlier than that of sFlt-1, it might be the better angiogenic factor 
for predicting preeclampsia. Serum sFlt-1 to PlGF ratio (sFLT-1/PIGF) 
was also suggested as screening parameter. An adenovirus-expressing 
sFlt-1 in rodents caused a clinical syndrome with glomerular 
endotheliosis, proteinuria, and hypertension. Glomerular capillary 
endotheliosis is another typical lesion in preeclampsia. 
Soluble endoglin: 
Serum levels of sEng in normal pregnancy are quite stable and 
slightly increase by 33-42 weeks of gestation. Placental endoglin is up-
regulated in preeclampsia and released in the circulation. Rising levels of 
circulating soluble endoglin (sEng) herald the onset of preeclampsia. 
Women with higher sEng levels at 21 through 32 weeks of gestation had 
an increased risk of preterm preeclampsia and an increased risk for a 
small-for-gestational-age infant. 
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Cellfree fetal DNA: 
Cellfree fetal DNA (cffDNA) is increased at 11-13 weeks of 
gestation in pregnancies that experience preeclampsia. Hypoxia within 
the intervillous space of the placenta leads to tissue oxidative stress and 
increases placental apoptosis and necrosis. This might be the cause of 
increased levels of cffDNA. Elevated cffDNA is not specific for 
preeclampsia and is also seen in other conditions associated with 
placental pathology. 
WHO recommendations for prevention and treatment of 
preeclampsia [10]: 
Rest for Prevention and Treatment of Preeclampsia 
1. Advice to rest at home is not recommended as an intervention for 
the primary prevention of preeclampsia and hypertensive disorders 
of pregnancy in women considered to be at risk of developing 
those conditions. 
2. Strict bedrest is not recommended for improving pregnancy 
outcomes in women with hypertension (with or without 
proteinuria) in pregnancy.  
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Dietary Salt Restriction for Prevention of Pre-eclampsia 
3. Restriction in dietary salt intake during pregnancy with the aim of 
preventing the development of pre-eclampsia and its complications 
is not recommended. 
Calcium Supplementation during Pregnancy to Prevent Preeclampsia and 
Its Complications 
4. In areas where dietary calcium intake is low, calcium 
supplementation during pregnancy (at doses of 1.5–2.0 g elemental 
calcium/day) is recommended for the prevention of preeclampsia in 
all women, but especially in those at high risk of developing 
preeclampsia. 
Vitamin D Supplementation 
5. Vitamin D supplementation during pregnancy is not recommended 
to prevent the development of preeclampsia and its complications. 
Antioxidants for Prevention of Preeclampsia and Its Complications 
6. Individual or combined vitamin C and vitamin E supplementation 
during pregnancy is not recommended to prevent the development 
of preeclampsia and its complications. 
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Antiplatelets for Prevention of Preeclampsia 
7. Low-dose acetylsalicylic acid (aspirin, 75 mg/day) is recommended 
for the prevention of preeclampsia in women at high risk of 
developing the condition. 
8. Low-dose acetylsalicylic acid (aspirin, 75 mg/day) for the 
prevention of preeclampsia and its related complications should be 
initiated before 20 weeks of pregnancy. 
Antihypertensive Drugs and Diuretics 
9. Women with severe hypertension during pregnancy should receive 
treatment with antihypertensive drugs. 
10. The choice and route of administration of an antihypertensive drug 
for severe hypertension during pregnancy, in preference to others, 
should be based primarily on the prescribing clinician's experience 
with that particular drug, its cost and local availability. 
11. Diuretics, particularly thiazides, are not recommended for the 
prevention of preeclampsia and its complications. 
Magnesium Sulfate for Prevention and Treatment of Eclampsia 
12. Magnesium sulfate is recommended for the prevention of 
eclampsia in women with severe preeclampsia in preference to 
other anticonvulsants.  
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13. Magnesium sulfate is recommended for the treatment of women 
with eclampsia in preference to other anticonvulsants.  
14. The full intravenous or intramuscular magnesium sulfate regimens 
are recommended for the prevention and treatment of eclampsia.  
15. In settings where it is not possible to administer the full magnesium 
sulfate regimen, the use of magnesium sulfate loading dose 
followed by immediate transfer to a higher level health-care facility 
is recommended for women with severe preeclampsia and 
eclampsia.  
Corticosteroids for HELLP (haemolysis, elevated liver enzymes, low 
platelet count) Syndrome 
16. The use of corticosteroids for the specific purpose of treating 
women with HELLP syndrome is not recommended. 
Interventional versus Expectant Care for Severe Preeclampsia before 
Term 
17. Induction of labour is recommended for women with severe pre-
eclampsia at a gestational age when the fetus is not viable or 
unlikely to achieve viability within one or two weeks. 
18. In women with severe preeclampsia, a viable fetus, and before 34 
weeks of gestation, a policy of expectant management is 
recommended, provided that uncontrolled maternal hypertension, 
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increasing maternal organ dysfunction or fetal distress are absent 
and can be monitored. 
19. In women with severe preeclampsia, a viable fetus and between 34 
and 36 (plus 6 days) weeks of gestation, a policy of expectant 
management may be recommended, provided that uncontrolled 
maternal hypertension, increasing maternal organ dysfunction or 
fetal distress are absent and can be monitored.  
Induction of Labour for Preeclampsia at Term 
20. In women with severe preeclampsia at term, a policy of early 
delivery is recommended.  
21. In women with mild preeclampsia or gestational hypertension at 
term, induction of labour is recommended.  
Prevention and Treatment of Postpartum Hypertension 
22. In women treated with antihypertensive drugs antenatally, 
continued antihypertensive treatment postpartum is recommended. 
23. Treatment with antihypertensive drugs is recommended for severe 
postpartum hypertension.  
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AIMS  & OBJECTIVES 
• To estimate serum cystatin C and serum creatinine level in pre-
eclamptic primigravidae and compare it with controls. 
• To assess the diagnostic performance of serum Cystatin C in early 
detection of renal dysfunction in pre-eclamptic primigravidae by 
comparing it with serum Creatinine. 
BENEFITS OF THE STUDY 
The better marker of renal dysfunction in preeclampsia can be used 
in clinical settings –serum cystatin C / serum creatinine 
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METHODOLOGY 
1) Term primigravidae attending AN OPD who are diagnosed to have 
preeclampsia are included and compared to equal number of 
healthy matched normotensive pregnant women 
2) Detailed history, general examination, obstetric examination are 
performed 
3) Withdrawal of 5ml blood for serum cystatin C& serum creatinine 
estimation 
Cases - pre-eclampticprimigravidae in third trimester ofpregnancy 
Controls -  healthyprimigravidae in third trimester 
Inpatients and outpatients of O & G Department, GovtKilpauk 
medical college & Hospital, Chennai 
Estimation of serum Creatinine by Jaffe’s method. 
Estimation of Cystatin C by Nephelometric method 
STUDY DESIGN:- 
Case control study 
PLACE OF STUDY: 
Antenatal Outpatient Department, LABOR WARD AND 
ANTENATAL WARD Dept of Obstetrics & Gynaecology, Govt Kilpauk 
medical college & Hospital, Chennai 
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DURATION OF STUDY: 6 Months 
SAMPLE SIZE 
n=(r+1/r)σ2(Zb+Za/2)2/difference2 
n-sample size, 
r-ratio of cases to controls = 1 
Zb-the desired power of the study = 80% = 0.84 
Za/2-represents the desired level of statistical significance – 1.96 
σ -standard deviation= 0.4 
difference-effect size(the difference in means)= 0.52 
n = 10 
cases – 40 
control - 40 
INCLUSION CRITERIA:- 
• Pre-eclamptic  primigravidaein third trimester as cases 
• Healthy matched primigravidae in third trimester as controls 
EXCLUSION CRITERIA:  
 Pre-eclamptic multigravidae 
 Healthy multigravidae 
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 Known case of diabetes mellitus, renal disease and chronic 
 hypertension 
• Multiple pregnancy 
• Liver disease 
• Connective tissue disorders 
• Smoking 
• Alcoholism 
STATISTICAL ANALYSIS: 
The mean and standard deviation of serum cystatin C& serum 
creatinine in both cases and controls will be compared by student t test 
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STATISTICAL ANALYSIS: 
Serum Cystatin C and Serum creatinine were considered as the 
primary outcome variables. Presence or absence of Preeclampsia was 
considered as primary exposure variable. Age and gender are considered 
as other explanatory variables. Descriptive analysis of all the variables 
was done using mean and standard deviation for quantitative variables, 
frequency and percentage for categorical variables. The association 
between Preeclampsia and primary outcome variables was assessed by 
Independent Sample T-Test. Mean differences, their confidence intervals 
and p-value were calculated and presented. P value < 0.05 was considered 
as statistically significant.IBM SPSS version 21 was used for statistical 
analysis. 
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RESULTS 
A total of 80 participants were included in the final analysis. 
TABLE 1: 
DESCRIPTIVE ANALYSIS OF AGE IN STUDY GROUP (N=50) 
Parameter Mean±STD Median Max Min 
95% C.I.for EXP(B) 
Lower Upper 
AGE 
23.71 ± 
2.710 
23.00 29.00 20.00 23.11 24.32 
 
The mean age was 23.71 ± 2.710 in the study population. (Table 1) 
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FIGURE 1: BOX-WHISKER PLOT OF AGE 
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TABLE 2: 
DESCRIPTIVE ANALYSIS OF AGE GROUP IN STUDY GROUP 
(N=80) 
Age group Frequency Percent 
20 to 24 49 61.25% 
25 to 28 28 35% 
Above 28 3 3.75% 
Total 80 100% 
 
The number of people in the age group 20 to 24 were 49 (61.25%), 
age group 25 to 28 were 28 (35%) and above 28 years were 3 (3.75%). 
(Table 2) 
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FIGURE 2:  
PIE CHART OF AGE GROUP DISTRIBUTION IN STUDY 
GROUP (N=80) 
 
 
49
28
3
20 to 24
25 to 28
Above 28
 72 
 
  
 73 
 
 
TABLE 3: 
 DESCRIPTIVE ANALYSIS OF SYSTOLIC BP AND DIASTOLIC 
BP IN STUDY GROUP (N=80) 
Parameter Mean±STD Median Max Min 
95% C.I.for EXP(B) 
Lower Upper 
Systolic BP 134 ± 26.22 130.00 180.00 100.00 128.16 139.84 
Diastolic 
BP 
83 ± 19.31 85.00 120.00 60.00 78.70 87.30 
 
 The mean Systolic BP was 134 ± 26.22 and mean Diastolic BP was 
83 ± 19.31in the study population. (Table 3) 
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FIGURE 3:  
BOX-WHISKER PLOT OF SYSTOLIC BLOOD PRESSURE 
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FIGURE 4:  
BOX-WHISKER PLOT OF DIASTOLIC BLOOD PRESSURE 
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TABLE 4:  
DESCRIPTIVE ANALYSIS OF PREECLAMPSIA IN STUDY 
GROUP (N=80) 
PREECLAMPSIA Frequency Percent 
Yes 40 50.00% 
No 40 50.00% 
Total 80 100.00% 
 
 Out of 80 subjects, 40 (50.00%) has preeclampsia and 40 (50.00%) 
has no preeclampsia. (Table 3) 
FIGURE 3:  
BAR CHART OF PREECLAMPSIA DISTRIBUTION IN STUDY 
GROUP (N=80) 
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TABLE 5:  
DESCRIPTIVE ANALYSIS OF SERUM CYSTATIN C AND 
SERUM CREATININE IN STUDY GROUP (N=80) 
Parameter Mean±STD Median Max Min 
95% C.I.for EXP(B) 
Lower Upper 
SerumCYSTATINC 
0.692 ± 
0.302 
0.55 1.64 0.40 0.62 0.76 
SerumCREATININE 
0.707 ± 
0.236 
0.60 1.40 0.30 0.65 0.76 
 
 The mean serum cystatin C was0.692 ± 0.302 and the mean Serum 
creatinine was 0.707 ± 0.236.(table5) 
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FIGURE 5:  
BOX-WHISKER PLOT OF SERUM CYSTATIN C 
 
FIGURE 5(a):  
BOX-WHISKER PLOT OF SERUM CREATININE 
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TABLE 6:  
DESCRIPTIVE ANALYSIS OF URINE ALBUMIN IN STUDY 
GROUP (N=80) 
URINEALB Frequency Percent 
1+ 7 8.75% 
2+ 16 20% 
3+ 10 12.5% 
4+ 7 8.75% 
NIL 40 50% 
Total 80 100% 
 
 The number of subjects with Urine albumin 1+ was 7 (8.75%), 
with Urine albumin 2+ was 14 (20%), with Urine albumin 3+ was 10 
(12.5%), with Urine albumin 4+ was 7 (8.75%) and without Urine 
albumin was 42 (50%). (Table 6) 
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FIGURE6: 
 PIE CHART OF URINE ALBUMIN DISTRIBUTION IN STUDY 
GROUP (N=80) 
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TABLE 7:  
COMPARISON OF MEAN SERUM CYSTATIN C ACROSS 
STUDY GROUPS (N=80) 
Pre-
eclampsia 
Serumcystatin 
C 
Mean±STD 
Mean 
difference 
95% CI 
P 
value Lower Upper 
YES 0.895 ± 0.310 
0.41 0.30 0.50 <0.001 
NO 0.489 ± 0.064 
 
The mean of serum cystatin C among people with preeclampsia 
was 0.895 ± 0.310 and the mean serum cystatin C among people without 
preeclampsia was 0.489 ± 0.064 in the study population. Hence Serum 
Cystatin C was 0.41 units higher (95% CI 0.30 to 0.50, p value <0.00) in 
people with preeclampsia (Table 7) 
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ROC curve 
Variable Serum.CYSTATINC 
Serum.CYSTATIN C 
Classification variable PREECLAMPSIA 
  
Sample size   80 
Positive group :  PREECLAMPSIA = 1 40 
Negative group :  PREECLAMPSIA = 0 40 
  
Disease prevalence (%) unknown 
  
Area under the ROC curve (AUC)  
 Area under the ROC curve (AUC)  0.941875 
Standard Errora 0.0259 
95% Confidence intervalb 0.865947 to 0.981859 
z statistic 17.031 
Significance level P (Area=0.5) <0.0001 
a Hanley & McNeil, 1982 
b Binomial exact 
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FIGURE 7:  
COMPARISON OF SERUM CYSTATINC ACROSS STUDY 
GROUP (N=80) 
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TABLE 8: 
 COMPARISON OF SERUM CREATININE ACROSS STUDY 
GROUPS (N=80) 
Pre-
eclampsia 
Serum creatinine  
Mean ± STD 
Mean 
difference 
95% CI P 
value Lower Upper 
YES 0.856 ± 0.215 
0.30 0.21715 0.38085 <0.001 
NO 0.557 ± 0.144 
 
The mean of serum creatinine among people with preeclampsia 
was 0.856 ± 0.215 and the mean serum creatinine among people without 
preeclampsia was 0.557 ± 0.14in the study population. Hence Serum 
Creatinine was 0.30 units higher (95% CI 0.21 to 0.38, p value <0.001) in 
people with preeclampsia (Table 8) 
  
 86 
ROC curve 
Variable Serum.CREATININE 
Classification variable PREECLAMPSIA 
  
Sample size   80 
Positive group :  PREECLAMPSIA = 1 40 
Negative group :  PREECLAMPSIA = 0 40 
  
Disease prevalence (%) unknown 
  
Area under the ROC curve (AUC)  
  
Area under the ROC curve (AUC)  
0.875313 
Standard Errora 0.0387 
95% Confidence intervalb 0.782484 to 0.938622 
z statistic 9.692 
Significance level P (Area=0.5) <0.0001 
a Hanley & McNeil, 1982 
b Binomial exact 
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FIGURE 8:  
COMPARISON OF SERUM CREATININE ACROSS STUDY 
GROUP (N=80) 
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TABLE 8: 
 ASSOCIATION OF PREECLAMPSIA WITH URINEALBUMIN 
OF STUDY POPULATION (N=80) 
URINEALB 
PREECLAMPSIA 
Chi square value P value 
NO YES 
1+ 
0 7 
72.381 .000 
0.00% 20% 
2+ 
0 16 
0.00% 35.00% 
3+ 
0 10 
0.00% 25.00% 
4+ 
0 7 
0.00% 17.5% 
NIL 
40 nil 
95.24% 50% 
 
 None of the study subjects without preeclampsia had albuminuria. 
The proportion of subjects with 1+, 2+, 3+ and 4+ albuminuria was 
17.5%, 35%, 25% and 17.5% respectively in the study. 
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DISCUSSION 
Pre-eclampsia, a syndrome characterized by hypertension, 
proteinuria and systemic vasoconstriction, is one of the leading causes of 
maternal and fetal morbidity. Although the exact etiology of pre-
eclampsia is not clear, insufficient placental function is thought to play a 
pivotal role. Studies have shown the association of pre-eclampsia with 
deficiency in the trophoblast invasion of maternal spinal arteries, leading 
to poor perfusion of feto-placental unit. Cathepsins (cysteine-proteases) 
are considered to be important for trophoblast invasion while their inhi-
bitor, cystatin C, regulates this invasion to prevent formation of placenta 
accreta or percreta. 
Cystatin C is a low molecular weight (13.3KDa) protein having 
renal excretion. Serum levels of cystatin C are less dependent on age, sex, 
race and muscle mass compared to serum creatinine levels. Cross-
sectional studies have shown that serum levels of cystatin C are more 
precise in estimating kidney functions than serum creatinine. This may be 
because creatinine is actively secreted by proximal renal tubules and 
hence glomerular filtration rate, calculated by creatinine clearance, is 
overestimated in severe renal dysfunction. Serum levels of cystatin C are 
increased in normal pregnancy, especially in the third trimester. This has 
been attributed to altered renal handling of low molecular weight proteins 
in conjunction with a decreased GFR and increased synthesis by the feto-
placental unit or generalized phenomenon. 
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A study concerning serum levels of cystatin C in preeclampsia and 
normal pregnancy was published by Strevens et al[48]. These 
investigators have found serum cystatin C concentrations to be 
significantly elevated in preeclamptic patients compared to normal 
pregnant women. 
Our data regarding both cystatin C and creatinine levels are 
consistent with the previous studies of Shalvi Sharma et al[19] and Fauzia 
Jumaat et al. Karl Kristensen[21] et al, which showed elevated plasma 
concentrations of cystatin C in patients with preeclampsia at the time of 
diagnosis.  
In my study, the mean age group, gestational age and parity of both 
controls and cases was similar. Serum cystatin C concentrations were 
significantly higher in pre-eclamptic patients (0.895 ±0.310mg/L) 
compared to the healthy pregnant females (0.489 ± 0.064 mg/L) with p 
value of <0.001 (highly significant). Serum levels of cystatin C are 
increased in normal pregnancy, especially in the third trimester. This has 
been attributed to renal handling of low molecular weight proteins in 
conjunction with a decreased GFR and increased synthesis by the 
fetoplacental unit or generalized phenomenon.  
The levels of Cystatin C are further increased in pre-eclampsia, 
correlating with the functional and structural changes in kidneys. In a 
renal biopsy study Cystatin C levels were shown to correlate with the 
degree of glomerular endotheliosis, a typical histologic feature of pre-
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eclampsia. Since degree of endotheliosis has been considered to 
determine the severity of pre-eclampsia, it has been hypothesized that 
serum levels of Cystatin C can offer information regarding the severity of 
pre-eclampsia. 
In the present study also, serum Cystatin C levels were 
significantly higher in patients with pre-eclampsia than healthy pregnant 
females. On the other hand, serum creatinine levels did not show 
significant difference between the two groups. These results confirm the 
previous observations of Cystatin C being superior to serum creatinine for 
estimation of renal function in pre-eclampsia patients.  
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CONCLUSION 
Serum cystatin C appears to be a superior marker of renal function 
compared to serum creatinine in patients with preeclampsia and should be 
routinely included in the investigative work-up of these patients. 
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PROFORMA 
NAME         HUSBAND NAME 
AGE            PH NO. 
IP NO                                                          QUALIFICATION 
ADDRESS                                                   OCCUPATION 
SOCIOECONOMIC STATUS 
OBSTETRIC HISTORY   :- 
1. PARITY 
2. GESTATIONAL AGE 
3. LMP                                        EDD 
4. COMORBID ILLNESS 
5. COMPLAINTS IF ANY 
H/O HEADACHE 
H/O VISUAL DISTURBANCES 
H/O EPIGASTRIC PAIN 
H/O VOMITING 
H/O REDUCED URINE OUTPUT 
H/O DIFFICULTY IN BREATHING 
H/O BLEEDING PV 
MENSTRUAL HISTORY 
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MARITAL HISTORY 
PAST HISTORY                :-  
1) DIABETES MELLITUS 
2) HYPERTENSION 
3) CHRONIC RENAL FAILURE 
4) HEART DISESE 
5) TUBERCULOSIS 
6) DRUG INTAKE 
7) EPILEPSY 
GENERAL EXAMINATION:- 
PALLOR:                                                     HEIGHT                      
PEDAL EDEMA       WEIGHT                    
BMI                             BREAST 
THYROID         
VITALS: 
TEMPERATURE: 
PULSE: 
BP: 
CVS: 
RS: 
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PER ABDOMEN: 
INVESTIGATIONS:- 
SERUM CREATININE 
URINE ALBUMIN 
SERUM CYSTATIN C 
FOR CASES 
S.NO NAME AGE 
GESTATIONAL 
AGE 
BLOOD 
PRESSURE 
SERUM 
CREATININE 
SERUM 
CYSTATIN 
C 
       
 
FOR CONTROLS 
S.NO NAME AGE GESTATIONAL 
AGE 
BLOOD 
PRESSURE 
SERUM 
CREATININE 
SERUM 
CYSTATIN C 
       
 
 
SIGNATURE OF THE GUIDE     SIGNATURE OF THE INVESTIGATOR 
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